Serious adverse events among participants in the Centers for Disease Control and Prevention's Anthrax Vaccine and Antimicrobial Availability Program for persons at risk for bioterrorism-related inhalational anthrax.

@article{Tierney2003SeriousAE,
  title={Serious adverse events among participants in the Centers for Disease Control and Prevention's Anthrax Vaccine and Antimicrobial Availability Program for persons at risk for bioterrorism-related inhalational anthrax.},
  author={Bruce C. Tierney and Stacey W. Martin and Laura Franzke and Nina M Marano and Dori B. Reissman and Randy D Louchart and Joyce A Goff and Nancy E. Rosenstein and John L. Sever and Michael M. McNeil},
  journal={Clinical infectious diseases : an official publication of the Infectious Diseases Society of America},
  year={2003},
  volume={37 7},
  pages={905-11}
}
On 20 December 2001, the Centers for Disease Control and Prevention (CDC) initiated the Anthrax Vaccine and Antibiotic Availability Program (hereafter, the "Program") under an investigational new drug application with the US Food and Drug Administration. This Program provided options for additional preventive treatment for persons at risk for inhalation anthrax as a result of recent bioterrorism attacks who had concluded or were concluding a 60-day course of antimicrobial prophylaxis… CONTINUE READING
8 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-8 of 8 extracted citations

Similar Papers

Loading similar papers…